Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.58 |
| ▸ | HPGD | P15428 | 4/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.49 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29897285 | 0.94 | MAPT (0.58) | MAPTSMN1; SMN2HPGDNPC1RAB9A | |
| SCHEMBL6826390 | 0.94 | MAPT (0.58) | MAPTSMN1; SMN2HPGDNPC1RAB9A | |
| SCHEMBL1929875 | 0.93 | MAPT (0.60) | MAPTSMN1; SMN2HPGDNPC1RAB9A | |
| SCHEMBL6927577 | 0.87 | MAPT (0.60) | MAPTSMN1; SMN2HPGDNPC1RAB9A | |
| SCHEMBL4038925 | 0.85 | MAPT (0.65) | MAPTSMN1; SMN2HPGDNPC1RAB9A | |
| SCHEMBL4199965 | 0.85 | HTT (0.59) | MAPTSMN1; SMN2HPGDNPC1RAB9A | |
| SCHEMBL224123 | 0.85 | TDP1 (0.60) | MAPTSMN1; SMN2HPGDNPC1RAB9A | |
| SCHEMBL2086989 | 0.85 | MAPT (0.61) | MAPTSMN1; SMN2HPGDNPC1RAB9A | |
| SCHEMBL28351555 | 0.84 | MAPT (0.54) | MAPTSMN1; SMN2HPGDNPC1RAB9A | |
| SCHEMBL4045709 | 0.84 | MAPT (0.64) | MAPTSMN1; SMN2HPGDNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7956049-B2 | Melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-07 | — | — | US | disclosed |
| US-7592373-B2 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| US-20090221548-A1 | MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-09-03 | — | — | US | disclosed |
| US-7553836-B2 | 7-(4-Chlorophenyl)-2-(3-methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one trifluoroacetic acid salt; obesity; antidiabetic agents; antidepressants; anxiolytic agents; combination with antipsychotic drugs enhanced therayp for schizophrenic disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1648448-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20080058515-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-03-06 | — | — | US | disclosed |
| US-20080058515-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-03-06 | — | — | US | disclosed |
| US-20080058515-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-03-06 | — | — | US | disclosed |
| US-7285557-B2 | Pyrimidinones as melanin concentrating hormone receptor 1 | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-10-23 | — | — | US | disclosed |
| US-7285557-B2 | Pyrimidinones as melanin concentrating hormone receptor 1 | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-10-23 | — | — | US | disclosed |
| EP-1442025-B1 | PYRIMIDINONES AS MELANIN CONCENTRATING HORMONE RECEPTOR 1 | SMITHKLINE BEECHAM PLC (GB) | 2007-03-07 | — | — | EP | disclosed |
| EP-1708698-A1 | 3-(4-PIPERIDINE-1YLMETHYL-PHENYL)-PROPION ACID-PHENYLAMIDE-DERIVATIVES AND RELATED COMPOUNDS USED IN THE FORM OF MCH ANTAGONISTS (MELANINE CONCENTRATING HORMONE) FOR TREATING EATING DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-11 | — | — | EP | disclosed |
| EP-1648448-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005063239-A9 | 3-(4-PIPERIDINE-1YLMETHYL-PHENYL)-PROPION ACID-PHENYLAMIDE-DERIVATIVES AND RELATED COMPOUNDS USED IN THE FORM OF MCH ANTAGONISTS (MELANINE CONCENTRATING HORMONE) FOR TREATING EATING DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2006-03-09 | — | — | WO | disclosed |
| US-20050267093-A1 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-01 | — | — | US | disclosed |
| WO-2005063239-A1 | 3-(4-PIPERIDINE-1YLMETHYL-PHENYL)-PROPION ACID-PHENYLAMIDE-DERIVATIVES AND RELATED COMPOUNDS USED IN THE FORM OF MCH ANTAGONISTS (MELANINE CONCENTRATING HORMONE) FOR TREATING EATING DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | WO | disclosed |
| WO-2005011681-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-10 | — | — | WO | disclosed |
| US-20040220404-A1 | Pyrimidinones as melanin concentrating hormone receptor 1 | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-11-04 | — | — | US | disclosed |
| EP-1442025-A1 | PYRIMIDINONES AS MELANIN CONCENTRATING HORMONE RECEPTOR 1 | SMITHKLINE BEECHAM PLC (GB) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003033476-A1 | PYRIMIDINONES AS MELANIN CONCENTRATING HORMONE RECEPTOR 1 | SMITHKLINE BEECHAM PLC (GB) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221548-A1 | MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | MCHR1, MCHR2, MC1R | MAPT 1561/4885SMN1; SMN2 1853/4885HPGD 2002/4885 |
| US-20040220404-A1 | Pyrimidinones as melanin concentrating hormone receptor 1 | MC1R, MCHR1, MCHR2 | MAPT 2954/4885SMN1; SMN2 2043/4885HPGD 360/4885 |
| US-20080058515-A1 | Chemical Compounds | SGK1, SGK2, SGK3 | MAPT 2294/4885SMN1; SMN2 3237/4885HPGD 1640/4885 |
| US-20050267093-A1 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, MC4R, MCHR2 | MAPT 4341/4885SMN1; SMN2 2771/4885HPGD 2648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.